News from janssen r A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 28, 2015, 08:00 ET

Janssen lanza iniciativa en la comunidad hispana en EE. UU. para ayudar a mejorar el cuidado de la diabetes tipo 2

Janssen Pharmaceuticals, Inc., fabricante de INVOKANA® (canagliflozina) para el tratamiento de la diabetes tipo 2, anunció hoy el...

Apr 28, 2015, 08:00 ET
Why U.S. Hispanics Require a Tailored Approach to Type 2 Diabetes Care

Janssen Launches U.S. Hispanic Community Initiative to Help Improve Type 2 Diabetes Care

 Janssen Pharmaceuticals, Inc., the manufacturer of INVOKANA® (canagliflozin) for the treatment of type 2 diabetes, today announced the...

Apr 23, 2015, 03:00 ET
Janssen Logo.

Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis

Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced results for its...

Apr 15, 2015, 08:30 ET

Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia

 A study published in The Journal of Clinical Psychiatry yesterday shows that long-acting INVEGA SUSTENNA® (paliperidone palmitate) was...

Apr 08, 2015, 05:00 ET
Janssen Logo

Janssen Highlights Hepatitis C Virus Development Program at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL)

 Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced that clinical...

Apr 02, 2015, 16:07 ET

Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution to Depomed, Inc.

 Janssen Pharmaceuticals, Inc. (JPI) today announced it has completed the divestiture of its U.S. license rights to NUCYNTA® (tapentadol),...

Apr 01, 2015, 08:00 ET

Janssen Therapeutics Announces Support for Organizations Focused on Improving Care and Treatment for People Who Inject Drugs Living with HIV and/or Hepatitis C

 Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the recipients of funding from a special request for...

Mar 30, 2015, 09:00 ET

New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia

Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in...

Mar 30, 2015, 08:00 ET

FDA Approves Label Update for ZYTIGA® to Include Statistically Significant Overall Survival Results in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer

 The U.S. Food and Drug Administration (FDA) has approved a label update for ZYTIGA® (abiraterone acetate) plus prednisone based on...

Mar 29, 2015, 02:31 ET

New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia

 Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in...

Mar 24, 2015, 06:02 ET

Janssen entwickelt Online-Plattform "EU Disease Lens"

Allein in Europa leiden mehr als 100.000 Menschen an Tuberkulose - eine Zahl, die rund um den Welt-Tuberkulosetag am 24.3. die Bedrohung...

Mar 24, 2015, 05:00 ET

DISEASE LENS ofrece información y visibilidad y de enfermedades relevantes

El panel  de datos interactivos agrega y muestra datos de salud europeos en 15enfermedades  y 28...

Mar 24, 2015, 05:00 ET

L'EU Disease Lens permet d'avoir une vision claire et précise des maladies les plus répandues en Europe

Un tableau de données interactif regroupe et affiche les données sanitaires de 15 maladies répandues sur 28 pays...

Mar 24, 2015, 05:00 ET

"EU Disease Lens" geeft visibiliteit en inzicht in de meest kritische ziektes

Interactief datadashboard verzamelt en geeft Europese gezondheidsgegevens weer over 15 belangrijke ziektegebieden en 28...

Mar 19, 2015, 04:00 ET

Janssen Acquires XO1 Limited

Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired...

Mar 16, 2015, 15:07 ET

Phase 3 Study with IMBRUVICA® (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression

 Janssen Research & Development, LLC (Janssen) announced today that a pre-planned interim analysis of the Phase 3 HELIOS (CLL3001) study...

Mar 02, 2015, 08:00 ET

Findings to be Presented at Annual Scientific Session of the American College of Cardiology (ACC) About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO®

 Full results from a Phase 3 study examining Portola Pharmaceutical's developmental compound andexanet alfa found it rapidly and significantly...

Feb 12, 2015, 06:15 ET

Janssen Sets A Course To Intercept Type 1 Diabetes Together With JDRF

Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it...

Feb 12, 2015, 06:00 ET

Janssen Launches Three New Research Platforms Focused on Redefining Healthcare

 Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today the...

Feb 09, 2015, 06:00 ET
Janssen Logo.  (PRNewsFoto/Janssen Pharmaceutical Companies)

La CE aprueba la indicación adicional para VELCADE® (bortezomib) en linfoma de células del manto

Este comunicado de prensa está originalmente escrito en inglés. PR Newswire proporciona las traducciones en alemán, francés y...